|
|||||
|
|

Aerospace and defense company Cadre (NYSE:CDRE) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 42.5% year on year to $155.9 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $627 million at the midpoint. Its non-GAAP profit of $0.38 per share was 37% above analysts’ consensus estimates.
Is now the time to buy CDRE? Find out in our full research report (it’s free for active Edge members).
Cadre’s third quarter results were met positively by the market, reflecting strong operational execution and notable progress in both core and emerging business areas. Management attributed the quarter’s performance to broad-based margin improvements across major categories, fueled by disciplined pricing, favorable product mix, and productivity initiatives. CEO Warren Kanders pointed to robust demand for explosive ordnance disposal (EOD) products and a significant $20 million sequential increase in backlog as key contributors. The recent Blast Exposure Monitoring System award—a $50 million contract with the U.S. Department of Defense—was highlighted as a milestone achievement for the company’s Med-Eng unit.
Looking ahead, Cadre’s guidance is underpinned by expectations of continued momentum in core markets and the anticipated benefits of the TYR Tactical acquisition. Management emphasized the company’s ability to integrate complementary businesses, expand market reach, and leverage advanced manufacturing capabilities, particularly in armor solutions. CFO Blaine Browers noted that while the addition of TYR Tactical may introduce some short-term gross margin pressure from integration costs, the transaction is expected to be accretive to adjusted EBITDA. The leadership team is also monitoring government spending patterns and large contract opportunities, with President Brad Williams stating, “We feel like we’ve got any of those potential slippages covered in the Q4 guidance side of things.”
Cadre’s latest quarter benefited from strong demand in core safety segments, enhanced by backlog growth and strategic M&A, while management highlighted broad improvements across business units.
Management expects Cadre’s performance in upcoming quarters to hinge on successful integration of acquisitions, execution on large contracts, and resilience in government-related demand.
In the upcoming quarters, the StockStory team will be closely monitoring (1) the pace and profitability of integrating TYR Tactical into Cadre’s platform, (2) the conversion of large backlog orders—especially the BEMO contract—into realized revenue, and (3) the company’s ability to mitigate any disruptions from government spending delays or shutdowns. Progress in these areas will be critical to sustaining margin expansion and growth.
Cadre currently trades at $44.21, up from $42.60 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free for active Edge members).
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Nov-05 | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-03 | |
| Nov-02 | |
| Oct-30 | |
| Oct-29 | |
| Oct-23 | |
| Oct-22 | |
| Oct-21 | |
| Oct-01 | |
| Sep-23 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite